Beaufort Securities view on Evgen Pharma (LON:EVG): This is an important and necessary appointment. Evgen is on course to commence two phase II clinical trials this year. This is the stage at which the Group needs to put together the right team with deep clinical experience in preparation for developing and implementing strategies for its indications. It also needs to sound out potential partnerships with a view to considering alliances capable of co-developing products and optimising pipeline potential. Dr Patel has an impressive industry track record and a breadth of relevant clinical experience, particularly given her key role with the successful filing, approval and commercial launch of a new indication for VELCADE in over 35 countries worldwide. As such, her appointment represents a key hire for Evgen while strengthening its core team. Therefore, we maintain our Speculative Buy rating on the stock.
Evgen Pharma plc, the clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce the appointment of Dr Hamina J Patel MB BCh MSc MRCPI as Chief Medical Officer. Dr Patel is a pharmaceutical executive with more than 15 years industry experience, leading global cross functional teams in the development and commercialisation of drugs primarily within the field of oncology. She was previously Director of Drug Development specialising in Oncology, at Johnson and Johnson, where she helped to build a broad and differentiated portfolio of indications. During this time, Dr Patel was also instrumental in the success of a new indication (the second-line treatment of mantle cell lymphoma) based on a Phase II clinical study.
